- Reports Broad-Based Net Sales Growth of 20% from Continuing Operations
Driven by Strong Performance of Pharmaceutical Business - Records Pre-Tax Earnings from Continuing Operations of $1.3 Billion
Representing an Increase of 51% From First Quarter 2007 - Posts First Quarter 2008 GAAP EPS from Continuing Operations of $0.35
Compared to $0.33 in 2007 and Double-Digit Non-GAAP EPS Growth from
Continuing Operations of $0.42 Compared to $0.36 in 2007 - Reaffirms 2008 EPS Guidance and 2007-2010 Expected 15% Non-GAAP EPS CAGR - Announces Plan to File Initial Public Offering of Approximately 10% of
Mead Johnson Nutritionals
NEW YORK, April 24 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today reported strong double-digit net sales growth and solid earnings growth for the first quarter 2008 and reaffirmed 2008 earnings guidance.
"Our medicines are performing well, as was evident this quarter, and our pipeline is steadily advancing. This is good news for patients and healthcare professionals who count on us, as well as shareholders who invest in us," said James M. Cornelius, chairman and chief executive officer, Bristol-Myers Squibb. "As we have pledged to patients and investors, we remain focused on discovering and developing medicines that will help people prevail in their fight against serious disease. We continue to review options within our "String of Pearls" strategy, to further complement our existing pipeline, technology and talent pool.
"We also continue to invest in our business as we embed a mindset of
continuous improvement, which is helping us grow our profit margins. Our
strong first quarter performance and our focus
|SOURCE Bristol-Myers Squibb Company|
Copyright©2008 PR Newswire.
All rights reserved